Uswm Ct, Llc

This expanded access program offers a cell therapy called afamitresgene autoleucel (afami-cel) to people with synovial sarcoma or myxoid liposarcoma whose manufactured dose didn't meet commercial standards. Eligible patients have no other feasible treatment options. The therapy i…

This study tests a new treatment called afamitresgene autoleucel in children and young adults aged 2 to 21 with advanced cancers that have a specific marker (MAGE-A4). The treatment uses the patient's own immune cells, modified to attack the cancer. The main goals are to check sa…

This study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …